USA's Code Red Compliance: Pure Global on Device Cybersecurity

The U.S. FDA has just escalated cybersecurity from a guideline to a mandatory gateway for market access. This episode of MedTech Global Insights unpacks the finalized guidance and its immediate, seismic impact on manufacturers of connected medical devices worldwide. We explore the immense operational challenges of new requirements like the Software Bill of Materials (SBOM) and proactive post-market threat monitoring. Discover the real-world impact through the case of a successful European infusion pump manufacturer. They believed their device was fully compliant in the U.S. market. Now, a mandatory retroactive software audit threatens their entire product roadmap and market presence. How can MedTech companies navigate these complex, resource-intensive demands without falling behind? This week you will learn: - What is a Software Bill of Materials and why is it now a non-negotiable FDA requirement? - How does the new guidance impact medical devices that are already on the market? - Why is your cybersecurity plan now as important as your clinical data for premarket submissions? - How will this aggressive U.S. standard influence future regulations in the EU and Asia? - What are the key elements of an effective post-market cybersecurity surveillance plan? - How can manufacturers manage vulnerabilities in third-party software components? - What are the unbudgeted costs your company needs to prepare for right now? For more information, contact us at [email protected], visit us at https://pureglobal.com/, or access our FREE AI tools and medical device database at https://pureglobal.ai/.